دورية أكاديمية
أعرض في EDS

Epidemiology of substance and opium use among adult residents of Tehran; a comprehensive report from Tehran cohort study (TeCS).

التفاصيل البيبلوغرافية
العنوان: Epidemiology of substance and opium use among adult residents of Tehran; a comprehensive report from Tehran cohort study (TeCS).
المؤلفون: Masoudkabir F; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran., Shafiee A; Tehran Heart Center , Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran, Iran., Heidari A; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran., Mohammadi NSH; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; Students' Scientific Research Center (SSRC), Tehran University of Medical Science, Tehran, Iran., Tavakoli K; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; Students' Scientific Research Center (SSRC), Tehran University of Medical Science, Tehran, Iran., Jalali A; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. arjalali@tums.ac.ir.; Department of Cardiovascular Research, Tehran Heart Center, North Kargar Ave, 1411713138, Tehran, Iran. arjalali@tums.ac.ir., Nayebirad S; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran., Alaeddini F; Tehran Heart Center , Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran, Iran., Saadat S; Department of Emergency Medicine, University of California, Irvine, CA, USA., Vasheghani-Farahani A; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran., Sadeghian S; Tehran Heart Center , Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran, Iran., Arita VA; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands., Boroumand M; Tehran Heart Center , Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran, Iran., Karimi A; Tehran Heart Center , Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran, Iran.
المصدر: BMC psychiatry [BMC Psychiatry] 2024 Feb 16; Vol. 24 (1), pp. 132. Date of Electronic Publication: 2024 Feb 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968559 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-244X (Electronic) Linking ISSN: 1471244X NLM ISO Abbreviation: BMC Psychiatry Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Opium Dependence*/epidemiology , Substance-Related Disorders*/epidemiology, Adult ; Female ; Humans ; Male ; Middle Aged ; Aged ; Cohort Studies ; Opium/adverse effects ; Iran/epidemiology ; Risk Factors
مستخلص: Background: The prevalence and burden of substance and opium use have increased worldwide over the past decades. In light of rapid population changes in Tehran, we aimed to evaluate the prevalence of opium and other substance use among adult residents in Tehran, Iran.
Method: From March 2016 to March 2019, we utilized data from 8 296 participants in the Tehran Cohort Study recruitment phase (TeCS). We calculated the age-sex-weighted prevalence of substance use and the geographic distribution of substance use in Tehran. We also used logistic regression analysis to determine possible determinants of opium use.
Result: We analyzed data from 8 259 eligible participants with complete substance use data and the average age of participants was 53.7 ± 12.75 years. The prevalence of substance use was 5.6% (95% confidence interval [CI]: 4.6- 7.1%). Substance use was more common in males than females (Prevalence: 10.5% [95% CI: 8.6- 12.6%] vs. 0.5% [95% CI: 0.2- 1.2%], respectively). The age-sex weighted prevalence of substance use was 5.4% (95% CI: 4.6-7.1%). Moreover, opium was the most frequently used substance by 95.8% of substance users. Additionally, we found that male gender (Odds ratio [OR]: 12.1, P < 0.001), alcohol intake (OR: 1.3, P = 0.016), and smoking (OR: 8.5, P < 0.001) were independently associated with opium use.
Conclusions: We found that the prevalence of substance use in Tehran was 5.6%, and opium was the most frequently used substance. In addition, male gender, lower levels of education, alcohol, and tobacco consumption are the main risk factors for substance use in Tehran. Healthcare providers and policymakers can utilize our results to implement preventive strategies to minimize substance use in Tehran.
(© 2024. The Author(s).)
References: Subst Abuse Treat Prev Policy. 2019 Feb 20;14(1):8. (PMID: 30786894)
Med J Islam Repub Iran. 2020 Mar 14;34:20. (PMID: 32551309)
Lancet. 2009 Jun 27;373(9682):2223-33. (PMID: 19560604)
Diabetes Metab Syndr. 2015 Oct-Dec;9(4):337-42. (PMID: 25470631)
Arch Iran Med. 2014 May;17(5):321-35. (PMID: 24784861)
Can J Psychiatry. 2014 Apr;59(4):203-12. (PMID: 25007113)
Lancet. 2012 Dec 15;380(9859):2224-60. (PMID: 23245609)
BMJ. 2008 May 3;336(7651):972. (PMID: 18456595)
Glob Heart. 2022 May 11;17(1):31. (PMID: 35586741)
Int J Prev Med. 2012 Jul;3(7):471-6. (PMID: 22891148)
Addict Health. 2020 Jan;12(1):46-57. (PMID: 32582415)
Int J Drug Policy. 2013 Nov;24(6):e115-6. (PMID: 23773684)
J Androl. 2012 Jul-Aug;33(4):515-28. (PMID: 21799144)
Subst Abuse Treat Prev Policy. 2020 Jul 29;15(1):52. (PMID: 32727512)
MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):349-358. (PMID: 29596405)
Subst Abus. 2020;41(1):35-69. (PMID: 31403903)
Subst Abuse Treat Prev Policy. 2020 Jun 5;15(1):39. (PMID: 32503660)
Ann N Y Acad Sci. 2008 Oct;1141:105-30. (PMID: 18991954)
Lancet. 2012 Jan 7;379(9810):55-70. (PMID: 22225671)
Arch Iran Med. 2017 Apr;20(4):205-210. (PMID: 28412823)
Healthcare (Basel). 2023 Apr 20;11(8):. (PMID: 37108016)
Int J High Risk Behav Addict. 2014 Sep 17;3(4):e21765. (PMID: 25741482)
Arch Iran Med. 2015 Aug;18(8):480-5. (PMID: 26265515)
Lancet. 2017 Sep 16;390(10100):1211-1259. (PMID: 28919117)
Addict Health. 2010 Summer-Autumn;2(3-4):103-10. (PMID: 24494108)
Glob Epidemiol. 2021 Mar 26;3:100051. (PMID: 37635720)
Health Promot Perspect. 2023 Sep 11;13(3):198-201. (PMID: 37808943)
J Addict. 2013;2013:297378. (PMID: 24804141)
Int J Drug Policy. 2019 Nov;73:36-41. (PMID: 31336292)
Iran J Public Health. 2020 Oct;49(10):1940-1946. (PMID: 33346232)
PLoS One. 2015 Feb 06;10(2):e0116820. (PMID: 25658103)
Lancet Psychiatry. 2018 Dec;5(12):987-1012. (PMID: 30392731)
Int J Health Policy Manag. 2018 Dec 31;8(4):222-232. (PMID: 31050967)
BMC Public Health. 2023 Apr 21;23(1):740. (PMID: 37085856)
BMC Endocr Disord. 2022 Oct 17;22(1):248. (PMID: 36253738)
Lancet. 2013 Nov 9;382(9904):1564-74. (PMID: 23993281)
Addict Behav. 2006 Aug;31(8):1469-76. (PMID: 16309848)
Arch Iran Med. 2019 Oct 01;22(10):541-545. (PMID: 31679354)
Hypertension. 2019 May;73(5):e35-e66. (PMID: 30827125)
Health Psychol Rev. 2016 Sep;10(3):297-312. (PMID: 26262912)
BMJ. 2012 Apr 17;344:e2502. (PMID: 22511302)
Addiction. 2016 Oct;111(10):1836-47. (PMID: 27177849)
Int J Drug Policy. 2014 Mar;25(2):196-203. (PMID: 24332455)
معلومات مُعتمدة: Internal fund Tehran Heart Center; Internal fund Tehran Heart Center; Internal fund Iranian Ministry of Health; Internal fund Iranian Ministry of Health
فهرسة مساهمة: Keywords: Addiction; Iran; Opium; Prevalence; Substance use; Tehran
المشرفين على المادة: 8008-60-4 (Opium)
تواريخ الأحداث: Date Created: 20240216 Date Completed: 20240219 Latest Revision: 20240219
رمز التحديث: 20240219
مُعرف محوري في PubMed: PMC10870582
DOI: 10.1186/s12888-024-05561-1
PMID: 38365633
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-244X
DOI:10.1186/s12888-024-05561-1